PYC Therapeutics (ASX:PYC) ROCE %: -28.95% (As of Dec. 2025)


ASX:PYC PYC Therapeutics Ltd ASX:PYC
35 GF Score
Price A$1.54
! 1 Warning Sign
View Full Analysis

What is PYC Therapeutics ROCE %?

PYC Therapeutics ASX:PYC 35 ROCE % is -28.95% as of Dec. 2025. GuruFocus rates ASX:PYC with a GF Score™ of 35/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. PYC Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2025 was -28.95%.

PYC Therapeutics  (ASX:PYC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

PYC Therapeutics ROCE % Related Terms

PYC Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for PYC Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PYC Therapeutics ROCE % Chart

PYC Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -43.34 -29.83 -66.92 -68.65 -40.26

PYC Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -101.66 -80.67 -74.36 -44.09 -28.95
ASX:PYC
35GF Score
PYC Therapeutics Ltd ASX:PYC
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PYC Therapeutics ROCE % Calculation

PYC Therapeutics's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=-50.951/( ( (91.239 - 9.107) + (183.279 - 12.317) )/ 2 )
=-50.951/( (82.132+170.962)/ 2 )
=-50.951/126.547
=-40.26 %

PYC Therapeutics's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-46.192/( ( (183.279 - 12.317) + (159.13 - 11.011) )/ 2 )
=-46.192/( ( 170.962 + 148.119 )/ 2 )
=-46.192/159.5405
=-28.95 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -28.95% mean?
PYC Therapeutics (ASX:PYC) has a ROCE % of -28.95% as of Dec. 2025.
Is PYC Therapeutics' ROCE % too high?
PYC Therapeutics' current ROCE % is -28.95%. Overall, PYC Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does PYC Therapeutics' ROCE % compare to VRTX and REGN?
PYC Therapeutics' ROCE % of -28.95% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. PYC Therapeutics's current ROCE % is -28.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PYC Therapeutics stock overvalued right now?
PYC Therapeutics (ASX:PYC) has a current ROCE % of -28.95%. The current ROCE % is -28.95%. PYC Therapeutics' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For PYC Therapeutics (ASX:PYC), the current ROCE % is -28.95% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PYC Therapeutics Business Description

Other Exchanges PYCXF:USA
Address 6 Verdun Street, Harry Perkins Institute of Medical Research, Nedlands, Perth, WA, AUS, 6009
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.
35GF Score

Get the complete analysis for ASX:PYC

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.54
Price